 |
12 Diseases |  |
17 Trials |
|
17 Trials |  |
2487 News |  |
| «12...345678910111213...2425» |
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis. (Pubmed Central) - May 29, 2022
The long-term treatment with erenumab was well tolerated and showed sustained efficacy in patients with CM in whom prior preventive treatments had failed, with numerically greater treatment effects for 140 mg versus 70 mg.
- | Aimovig (erenumab-aooe) / Amgen, Novartis, Nurtec ODT (rimegepant ODT) / Pfizer
Journal: Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor. (Pubmed Central) - May 29, 2022
Our results demonstrate that erenumab and rimegepant are potent antagonists of CGRP-R and AMY-R with 32- and 25-times preference for the CGRP-R over the AMY-R, respectively. It is discussed if this difference in affinity between the two receptors is the likely reason why constipation is a common and serious adverse effect during CGRP-R antagonism but less so with CGRP binding antibodies.
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal, HEOR, Real-world evidence: Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. (Pubmed Central) - May 25, 2022
It is discussed if this difference in affinity between the two receptors is the likely reason why constipation is a common and serious adverse effect during CGRP-R antagonism but less so with CGRP binding antibodies. Patients affected by CM and MOH at the baseline displayed a significant worsening of their headaches after erenumab discontinuation.
- ||||| Aimovig (erenumab) / Amgen, Novartis
Clinical: Open Access: Long-term efficacy & safety of #erenumab in patients with #chronicmigraine in whom prior preventive treatments had failed: A subgroup analysis @MessoudAshina @StewartTepper @weatherallmw et al https://t.co/tXJeeCYaCp (Twitter) - May 21, 2022
- | Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Aimovig (erenumab) / Amgen, Novartis
Journal: Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache. (Pubmed Central) - May 19, 2022
Patients affected by CM and MOH at the baseline displayed a significant worsening of their headaches after erenumab discontinuation. Our results support the emerging evidence that anti-CGRP monoclonal antibodies may be effective in medication overuse headache patients irrespective of detoxification, yet further studies are needed to draw definitive conclusions.
- | Aimovig (erenumab) / Amgen, Novartis
Journal: Successful treatment of primary headache associated with sexual activity using erenumab: Case report. (Pubmed Central) - May 19, 2022
Our results support the emerging evidence that anti-CGRP monoclonal antibodies may be effective in medication overuse headache patients irrespective of detoxification, yet further studies are needed to draw definitive conclusions. The efficacy of erenumab in our case presumes that CGRP might also be an important mediator in facilitating primary headache associated with sexual activity.
- ||| Aimovig (erenumab) / Amgen, Novartis
Retrospective data, Journal, Adverse events, Real-world evidence: Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study. (Pubmed Central) - May 18, 2022
Furthermore, no habituation of AEs is observed. Nevertheless, females and patients with aura seem to be more prone to have AEs.
- |||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New trial, Real-world evidence, Real-world: REFI: Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities. (clinicaltrials.gov) - May 15, 2022
P=N/A, N=162, Completed, Sponsor: Novartis Pharmaceuticals
- ||| Aimovig (erenumab) / Amgen, Novartis
Over 30 years of migraines. Aimovig helping with devastating pain, but keep being told no help available for the overwhelming fatigue, and aches & pains & fuzzy thinking. And Dr. Starling is right—there are not enough neurologists treating migraine or treating it seriously. (Twitter) - May 6, 2022
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, P4 data, Journal: Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. (Pubmed Central) - May 6, 2022
P4
Nevertheless, females and patients with aura seem to be more prone to have AEs. Erenumab demonstrated a favourable tolerability and efficacy profile compared to topiramate.Trial registration: ClinicalTrials.gov NCT03828539, URL: https://clinicaltrials.gov/ct2/show/NCT03828539.
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies. (Pubmed Central) - May 6, 2022
Erenumab treatment significantly reduced WMD compared with placebo. Onset of erenumab efficacy occurred as early as Week 1 in patients with migraine.
- ||| Aimovig (erenumab) / Amgen, Novartis
Journal, Adverse events, Real-world evidence: Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. (Pubmed Central) - May 6, 2022
Nonetheless, CGRP blockade might be the last straw that disrupts the physiological balance of vascular response in patients at-risk of Raynaud's phenomenon. Pending further data regarding vascular safety of CGRP-targeting drugs, caution is warranted in these patients.
- ||||| Aimovig (erenumab) / Amgen, Novartis
Clinical: Chronic #migraine is the most common diagnosis of patients seen in tertiary #headache centres. Here, Dr. Peter Goadsby @petergoadsby demonstrates that erenumab is effective and well-received in patients with chronic migraine in tertiary #care settings. https://t.co/eFhTdEwGl7 (Twitter) - Apr 30, 2022
- | Aimovig (erenumab) / Amgen, Novartis
Journal: A Markov Analysis of Surgical versus Medical Management of Chronic Migraines. (Pubmed Central) - Apr 29, 2022
Surgical deactivation of migraine trigger sites may pose a cost-effective approach to treating refractory chronic migraine in adults. This is especially the case when patients are anticipated to require therapy for more than 1 year.
- || Aimovig (erenumab) / Amgen, Novartis
Review, Journal: The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review. (Pubmed Central) - Apr 26, 2022
This case is unique in that the mother continued to receive erenumab throughout the pregnancy. Safety data is lacking regarding the use of these agents during pregnancy, despite their frequent use in women of childbearing potential.
- || Aimovig (erenumab) / Amgen, Novartis
@Amgen @Aimovig So disappointed in the changes to the AimAlly program. Devoted user for 3+ years and now can’t afford it. Sad. (Twitter) - Apr 25, 2022
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal, Patient reported outcomes: Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey. (Pubmed Central) - Apr 22, 2022
• Almost 40% of patients experienced some wearing-off between injections. • Almost half of patients experience migraine rebounds after treatment cessation.
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Review, Journal: Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendations. (Pubmed Central) - Apr 22, 2022
• Almost half of patients experience migraine rebounds after treatment cessation. Cumulative data from the literature support a therapeutic gain with an increase from erenumab 70 to 140 mg and a rationale for initiating 140 mg in selected patients.
- | Aimovig (erenumab) / Amgen, Novartis
Observational data, Journal, Real-world evidence: A real-world, observational study of erenumab for migraine prevention in Canadian patients. (Pubmed Central) - Apr 22, 2022
One-third of patients with EM and CM achieved ≥50% MMD reduction after 3 months of erenumab treatment. This study provides real-world evidence of erenumab effectiveness, safety, and usage for migraine prevention in adult Canadian patients with multiple prior ineffective prophylactic treatments.
- | Aimovig (erenumab) / Amgen, Novartis
Journal, Real-world evidence: Effectiveness and safety of erenumab in chronic migraine: A Croatian real-world experience. (Pubmed Central) - Apr 15, 2022
This study provides real-world evidence of erenumab effectiveness, safety, and usage for migraine prevention in adult Canadian patients with multiple prior ineffective prophylactic treatments. Our study indicates that erenumab is a safe and effective therapeutic option for chronic migraine patients.
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, Aimovig (erenumab) / Amgen, Novartis
Retrospective data, Journal: A retrospective evaluation of the combination of erenumab and onabotulinum toxin A for the prevention of chronic migraine. (Pubmed Central) - Apr 15, 2022
Our study indicates that erenumab is a safe and effective therapeutic option for chronic migraine patients. This retrospective case series showed a reduction in monthly migraine and headache days with the treatment combination of erenumab and onabot A compared to onabot A alone in patients with chronic migraine.
- | Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Aimovig (erenumab) / Amgen, Novartis
Journal: Predictors of Sustained Response and Effects of Anti-CGRP Antibodies Discontinuation and Reinitiation in Resistant Chronic Migraine. (Pubmed Central) - Apr 13, 2022
In most patients, the 3-month discontinuation of anti-CGRP mAbs resulted in progressive migraine deterioration that was rapidly reverted by retreatment. However, one-quarter of patients who reported better quality of life indices before treatment showed a sustained benefit during discontinuation and did not need retreatment.
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Review, Journal: Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes. (Pubmed Central) - Apr 13, 2022
Further studies will provide insights on optimal treatment duration to achieve migraine remission and predictors of treatment response. In the present work, we aimed at reviewing design and results of the main studies on erenumab and discussing treatment use in the current migraine prevention scenario; we also summarized the main ongoing research projects and provided clinical perspectives for the future.
- ||||| Aimovig (erenumab) / Amgen, Novartis
Clinical, Observational data, Real-world evidence: Open Access: A real-world, observational study of #erenumab for #migraine prevention in Canadian patients @LerouxNeuro et al https://t.co/TC2MOdxv84 (Twitter) - Apr 12, 2022
- | Aimovig (erenumab) / Amgen, Novartis
Observational data, Journal: Change in the second exteroceptive suppression period of the temporalis muscle during erenumab treatment. (Pubmed Central) - Apr 12, 2022
The change observed in the temporalis ES2 during erenumab treatment indicates that ES2 may play some kind of role as a neurophysiological marker and that this monoclonal antibody can modulate the brainstem circuits involved in migraine pathophysiology, at least indirectly. Further studies are required to confirm this intriguing hypothesis.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: CGRP-1: CGRP Inhibition, Autonomic Function, and Migraine (clinicaltrials.gov) - Apr 11, 2022
P=N/A, N=120, Recruiting, Sponsor: Medical University of Vienna
Further studies are required to confirm this intriguing hypothesis. Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Feb 2022 --> Feb 2024
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE) (clinicaltrials.gov) - Apr 10, 2022
P2, N=60, Recruiting, Sponsor: University of Maryland, Baltimore
Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Feb 2022 --> Feb 2024 Not yet recruiting --> Recruiting
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: Erenumab-aooe for the Management of Trigeminal Neuropathic Pain. (clinicaltrials.gov) - Apr 10, 2022
P2, N=40, Recruiting, Sponsor: University of Maryland, Baltimore
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Aimovig (erenumab) / Amgen, Novartis
Sustained benefit of monthly erenumab versus daily oral preventives in episodic migraine patients from APPRAISE study (A9) - Apr 9, 2022 - Abstract #EAN2022EAN_869;
Not yet recruiting --> Recruiting Erenumab showed sustained superior efficacy compared with oral preventives in patients with EM who had previously failed 1 or 2 migraine preventives.
- Aimovig (erenumab) / Amgen, Novartis
Is MIDAS reduction at 3 months the best indicator for erenumab treatment continuation? A real-world experience (A9) - Apr 9, 2022 - Abstract #EAN2022EAN_866;
MIDASr at T3 is a predictor of long-term response, but, when used as single decision-making step, it excludes nearly 40% of future 1-year erenumab responders according to migraine days. A criterion based on the combined evaluation of MIDASr and 50% reduction in MMDs at T3 may represent a more precisely predictive option.
- Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Predictors of response to antiCGRP monoclonal antibodies: a multicenter, 24-week, cohort study on 864 migraine patients (A8) - Apr 9, 2022 - Abstract #EAN2022EAN_729;
Peripheral trigeminal sensitization symptoms (UP + UAs) alone, on association with central sensitization ones (allodynia) seem to predict ≥50% and ≥75% response to antiCGRP mAbs. .
- Aimovig (erenumab) / Amgen, Novartis
Final results from a real world evidence study on the treatment of migraine patients with Erenumab In GERMANY (SPECTRE) (A8) - Apr 9, 2022 - Abstract #EAN2022EAN_727;
. SPECTRE will provide valuable insights into use of erenumab in clinical practice in Germany, help characterize prescription patterns and analyze the respective therapy response.
- Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Late response to anti-CGRP (calcitonin gene-related peptide) monoclonal antibodies: implication for clinical practice (Room Istanbul) - Apr 9, 2022 - Abstract #EAN2022EAN_264;
Late response to antiCGRP mAbs may occur in more than one third of migraine patients considered not responders at 12 weeks. Our findings suggest extending the efficacy treatment evaluation for antiCGRP mAbs to 6 months, also in terms of reimbursement policies.
- Aimovig (erenumab) / Amgen, Novartis
CGRP plasma levels in migraine patients before and after CGRP monoclonal antibodies therapy (Room Istanbul) - Apr 9, 2022 - Abstract #EAN2022EAN_263;
CGRP levels increase significantly after the therapy. Further studies with more participants are needed to confirm these data.
- | Aimovig (erenumab) / Amgen, Novartis
Journal: Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention. (Pubmed Central) - Apr 8, 2022
The timing of the new type of headache occurring 2 days post erenumab injection suggests a possible cause and effect relationship. Reversible cerebral vasoconstriction syndrome as a possible treatment-related complication to the usage of calcitonin gene-related peptide monoclonal antibodies needs to be studied further.
- || Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. (Pubmed Central) - Apr 8, 2022
Reversible cerebral vasoconstriction syndrome as a possible treatment-related complication to the usage of calcitonin gene-related peptide monoclonal antibodies needs to be studied further. The cessation of CGRP(-receptor) antibodies migraine prophylaxis was associated with a significant increase of migraine frequency and acute medication intake over time.
- | Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Retrospective data, Journal: Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study. (Pubmed Central) - Apr 8, 2022
Our findings demonstrate that a relevant proportion of erenumab non-responders might benefit from a treatment switch to a CGRP-mAb. Switching seems to be a promising treatment option especially in migraine patients with non-daily headache.
- | Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Journal, Real-world evidence: Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience. (Pubmed Central) - Apr 6, 2022
Switching seems to be a promising treatment option especially in migraine patients with non-daily headache. Reinitiation of treatment with CGRP(-R) mAbs after a drug holiday leads to a significant reduction of migraine frequency and medication use as well as improvement in quality of life.
- | Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo
Retrospective data, Journal: Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study. (Pubmed Central) - Apr 6, 2022
Largely similar results were observed for 6-month follow-up cohorts. Patients on CGRP mAb and specifically galcanezumab showed higher adherence and persistence than patients on SOC migraine preventive treatments.
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Clinic and genetic predictors in response to erenumab. (Pubmed Central) - Apr 5, 2022
Number of failed preventive medications, migraine burden, and age at migraine onset predicted response to ERE. Larger studies are required to confirm a possible role of RAMP1 rs7590387 as genetic predictor of ERE efficacy.
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Treatment with the monoclonal CGRP-R antibody erenumab: A real life study. (Pubmed Central) - Apr 2, 2022
Erenumab was effective in migraine patients highly refractory to previous prophylactics. We propose as a practical guideline to continue treatment for at least six months and to consider patients with ≥30% MMD reduction in at least half of the treatment period to be responders.
- | Retrospective data, Journal, HEOR: Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials. (Pubmed Central) - Mar 31, 2022
Our NMA indicated that all four CGRP mAbs demonstrated excellent safety, acceptability, and efficacy profiles compared to the traditional prophylaxis for CM. However, because there are several limitations, the findings of the current NMA should be taken into consideration with caution.
- | Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Journal: Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score. (Pubmed Central) - Mar 23, 2022
In resistant chronic migraine patients, anti-CGRP mAbs are effective and safe. A ≥ 50% reduction in MIDAS score seems to be the most advantageous outcome measure in this setting, which allows most severe migraine patients to persist with treatment.
- | Aimovig (erenumab) / Amgen, Novartis
Journal: Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. (Pubmed Central) - Mar 23, 2022
The present study shows that even patients with good relative response to erenumab may have a clinically non-negligible residual migraine burden. Relative measures of efficacy cannot be enough to thoroughly consider the efficacy of migraine prevention.
- Aimovig (erenumab) / Amgen, Novartis
What a Headache: Erenumab Provoked Urticarial Drug Eruption () - Mar 21, 2022 - Abstract #AAD2022AAD_2691;
Other hypersensitivity reactions including angioedema and anaphylaxis have been reported. Due to the increasing evidence, the FDA revised the drug label in 2019 to include a warning regarding "hypersensitivity reactions, including rash, angioedema, and anaphylaxis.” This case adds to the growing evidence regarding immunogenicity of erenumab, and of the CGRP monoclonal antibodies as a class.
- | Aimovig (erenumab) / Amgen, Novartis
Journal: Erenumab Safe, Effective for Patients With Migraine With Aura. (Pubmed Central) - Mar 18, 2022
Due to the increasing evidence, the FDA revised the drug label in 2019 to include a warning regarding "hypersensitivity reactions, including rash, angioedema, and anaphylaxis.” This case adds to the growing evidence regarding immunogenicity of erenumab, and of the CGRP monoclonal antibodies as a class. No abstract available
- || Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Acute Medication Use in Patients With Migraine Treated With Monoclonal Antibodies Acting on the CGRP Pathway: Results From a Multicenter Study and Proposal of a New Index. (Pubmed Central) - Mar 18, 2022
We proposed a new index that can be easily applied in clinical practice to quantify migraine burden and its response to acute medication. Our index could help optimizing migraine acute treatment in clinical practice.
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder (clinicaltrials.gov) - Mar 17, 2022
P2, N=30, Recruiting, Sponsor: Indiana University
Our index could help optimizing migraine acute treatment in clinical practice. Trial completion date: Jun 2022 --> Jan 2023 | Trial primary completion date: May 2022 --> Dec 2022
- | Aimovig (erenumab) / Amgen, Novartis
Journal: The efficacy and safety of Erenumab in patients with high-frequency episodic migraine according to the first Russian real-life study of the Research Center of Neurology (Pubmed Central) - Mar 17, 2022
Trial completion date: Jun 2022 --> Jan 2023 | Trial primary completion date: May 2022 --> Dec 2022 Real-life study confirmed the efficacy and safety of Erenumab in the treatment of HFEM, a decrease in the severity of comorbid anxiety and depression, and social maladjustment.
- |||| Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
New P4 trial, HEOR, Real-world evidence, Real-world effectiveness, Real-world: EVEC: Real World Effectiveness of Eptinezumab in Participants With Migraine (clinicaltrials.gov) - Mar 16, 2022
P4, N=200, Recruiting, Sponsor: H. Lundbeck A/S